Successful Spinal Cord Stimulation for Necrotizing Raynaud's Phenomenon in COVID-19 Affected Patient: The Nightmare Comes Back.
covid-19
pain
raynaud phenomenon
spinal cord stimulation
vascular pain
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
19 Apr 2021
19 Apr 2021
Historique:
entrez:
3
6
2021
pubmed:
4
6
2021
medline:
4
6
2021
Statut:
epublish
Résumé
Necrotizing Raynaud's phenomenon is a vascular clinical syndrome characterized by vasospasm of distal resistance vessels, usually triggered by cold temperatures or by psychological conditions such as anxiety and stress. Pain is the first reported symptom, related to insufficient oxygen delivery to the extremities that leads to ischemia of the peripheral tissues. The initial treatment is conservative, but if the symptoms persist, necrosis and distal amputation can occur. In selected patients, neuromodulation with spinal cord stimulation (SCS) can be an effective treatment by reducing pain and amputation rate. Recent evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause endotheliopathy with microvascular and macrovascular thrombotic events and can present as a systemic inflammatory vascular disease. We present a case of a severe necrotizing Raynaud's phenomenon successfully treated and controlled with SCS that abruptly reappeared during SARS-CoV-2 infection. The report of this case is suggestive for potential treatment in case of peripheral ischemia consequent to COVID-19 vasculopathy. The interaction between SCS and SARS-CoV-2-related endotheliopathy is unknown and would deserve further studies.
Identifiants
pubmed: 34079662
doi: 10.7759/cureus.14569
pmc: PMC8159305
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e14569Informations de copyright
Copyright © 2021, Giglio et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuromodulation. 2011 May-Jun;14(3):229-33; discussion 233-4
pubmed: 21992245
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Inflamm Res. 2020 Dec;69(12):1181-1189
pubmed: 32918567
Cureus. 2021 Mar 15;13(3):e13892
pubmed: 33880248
Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):561-567
pubmed: 33004167
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
Am J Physiol. 1997 Feb;272(2 Pt 2):H950-7
pubmed: 9124459
Pain Pract. 2011 Sep-Oct;11(5):483-91
pubmed: 21435165
Anesth Pain Med. 2020 Apr 25;10(2):e103819
pubmed: 32754437
Pain Physician. 2007 May;10(3):473-8
pubmed: 17525782
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
Pain Med. 2010 Aug;11(8):1278-83
pubmed: 20704677
Auton Neurosci. 2008 Feb 29;138(1-2):9-23
pubmed: 18083639
J Thromb Thrombolysis. 2020 Oct;50(3):499-511
pubmed: 32700024
J Am Pharm Assoc (2003). 2020 Nov - Dec;60(6):e88-e90
pubmed: 32747165
Pain Pract. 2012 Jul;12(6):469-75
pubmed: 22304658
Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1672-80
pubmed: 14704229
J Natl Cancer Inst. 1986 Jun;76(6):1113-21
pubmed: 3458948
Adv Ther. 2020 Jan;37(1):113-139
pubmed: 31782132
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143